一、主要日常关联交易基本情况 关于多多药业 2024 年度预计主要日常关联交易的公告 共 10 页 证券代码：000931 证券简称：中关村 公告编号：2024-033 北京中关村科技发展（控股）股份有限公司 关于多多药业 2024 年度预计主要日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2024 年 4 月 17 日召开了第八届董事会第六次会议，审议并通过了《关于多多药业 2024 年度预计主要日常关联交易的议案》。现将具体情况公告如下： （一）关联交易概述 1、多多药业向多多集团采购水、电、蒸汽 公司之全资子公司北京中关村四环医药开发有限责任公司持有多多药业有 限公司（以下简称：多多药业）78.82%股份；黑龙江多多集团有限责任公司（以 下简称：多多集团）持有多多药业 20.98%股份。多多集团向多多药业提供能源 动力服务，依据双方 2023 年度关联交易实际情况，并结合多多药业 2024 年度生 产计划和经营预算，2024 年度向多多集团预计采购情况具体如下： | 项目 ...

第八届董事会第六次会议决议公告 共 8 页 证券代码：000931 证券简称：中关村 公告编号：2024-027 北京中关村科技发展（控股）股份有限公司 第八届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第八届董事 会第六次会议通知于 2024 年 4 月 7 日以专人送达、电子邮件或传真等方式发出， 会议于 2024 年 4 月 17 日上午 10 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场表决方式如期召开。会议应到董事 9 名，实到董事 9 名。 会议召开程序符合相关法律法规和《公司章程》的有关规定。经与会董事认真讨 论研究，形成以下决议： 一、审议通过《2023 年年度报告全文及摘要》； 表决结果：9 票同意，0 票反对，0 票弃权。 《2023 年度财务报告》已经董事会审计委员会审议通过。 具体内容详见与本公告同日披露的《2023 年年度报告》《2023 年年度报告 摘要》（公告编号：2024-029、030），本议案须提交公司股东 ...

北京中关村科技发展（控股）股份有限公司 2023 年度 募集资金存放与使用情况专项报告 北京中关村科技发展（控股）股份有限公司 2023 年度募集资金存放与使用情况的专项报告 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2016]2979 号文核准，中关村于 2017 年 1 月非公 开发行 78,280,042 股人民币普通股，每股面值 1.00 元，发行价格为每股 9.07 元。公司募 集资金总额为 709,999,980.94 元，扣除发行费用 10,088,279.81 元，本次发行募集资金净 额为 699,911,701.13 元。 截止 2017 年 1 月 25 日，本公司上述发行募集的资金已全部到位，业经中兴华会计师 事务所（特殊普通合伙）以"中兴华验字（2017）第 010009 号"验资报告验证确认。 截止 2023 年 12 月 31 日，公司对募集资金项目累计投入 699,911,686.13 元，其中： 公司于募集资金到位之前利用自有资金先期投入募集资金项目人民币 19,799.09 万元；于 2017 年 1 月 1 日起至 2022 年 12 月 31 日止会计期间使 ...

北京中关村科技发展(控股)股份有限公司 中兴财光华审会字(2024) 第 213187 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.mof.gov.cn）"进 所出 报告编码:京24NEVQCTVT 目录 审计报告 | 合并及公司资产负债表 | 1-2 | | --- | --- | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-111 | 审计报告 中兴财光华审会字(2024)第 213187 号 北京中关村科技发展(控股) 股份有限公司全体股东: 一、审计意见 我们审计了北京中关村科技发展(控股)股份有限公司(以下简称"中关村") 财务报表,包括 2023年 12月 31日的合并及公司资产负债表,2023年度的合并 及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务 报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了中关村 2023年12月31日的合并及公司财务状况以及 2023年度的合 并及公司经营成果和现金流 ...

Financial Performance - Consolidated revenue for 2023 reached 2.28 billion RMB, a year-on-year increase of 10.50%[25] - Net profit attributable to shareholders of the listed company was 487.82 million RMB, turning from a loss to a profit compared to the previous year[25] - Pharmaceutical and health products business revenue accounted for 75.85% of total revenue, reaching 1.73 billion RMB, a 15.35% increase year-on-year[26][31] - The company's concrete business revenue increased by 3.76% to 348.59 million RMB[31] - Revenue from the elderly care and medical business grew by 8.25% to 130.12 million RMB[31] - North and Northeast China regions contributed 57.83% of total revenue, reaching 1.32 billion RMB, a 15.74% increase year-on-year[31] - Sales revenue from the western region increased by 3.12% to 250,799,136.79 yuan, accounting for 11.02% of total revenue[44] - Distribution sales increased by 15.35% to 1,726,774,797.92 yuan, accounting for 75.85% of total revenue[44] - Direct sales decreased by 2.38% to 549,828,547.83 yuan, accounting for 24.15% of total revenue[44] - Total sales from top 5 customers amounted to 220,925,873.75 yuan, accounting for 9.71% of the annual sales[63] - Non-recurring gains and losses for 2023 totaled RMB 13.22 million, an increase from RMB 7.35 million in 2022[101] - Government subsidies recognized in 2023 amounted to RMB 17.67 million, up from RMB 11.48 million in 2022[101] - The company expects consolidated operating revenue and net profit attributable to shareholders to grow in 2024 compared to 2023[146] R&D and Innovation - The company's R&D team completed project initiation for multiple new products in cardiovascular, psychiatric, and respiratory fields[28] - The company's R&D project for Naloxone Hydrochloride Injection (consistency evaluation) has obtained the "Acceptance Notice" on December 18, 2023, and is currently under CDE review and approval[57] - The R&D project for Naltrexone Hydrochloride Tablets (consistency evaluation) is undergoing process validation, aiming to obtain production approval[57] - The R&D project for Buspirone Hydrochloride Tablets (consistency evaluation) has completed small-scale research and aims to obtain production approval[57] - The R&D project for Tramadol Hydrochloride Tablets (consistency evaluation) has completed process research and aims to obtain production approval[57] - The R&D project for Oxycodone Hydrochloride Extended-Release Tablets has completed pilot-scale research and aims to obtain production approval[57] - The R&D project for Arotinolol Hydrochloride Tablets has initiated small-scale research and aims to obtain production approval[58] - The R&D project for Methylphenidate Hydrochloride Extended-Release Chewable Tablets has completed small-scale research and is preparing for pilot-scale research, aiming to obtain production approval[58] - The R&D project for Bifonazole API has completed process validation for production site change and submitted registration materials, currently under CDE review[58] - The R&D project for Huperzine A API is undergoing small-scale research and aims to obtain API registration[58] - The R&D project for Paracetamol and Tramadol Hydrochloride Tablets (consistency evaluation) obtained the "Drug Supplement Application Approval Notice" on April 18, 2023[58] - R&D personnel increased by 6.86% to 218 in 2023, with a 14.58% increase in employees under 30 years old[83] - R&D investment decreased by 13.47% to 106,773,729.12 yuan in 2023, accounting for 4.69% of operating revenue[83] - Capitalized R&D investment increased by 77.10% to 3,276,449.79 yuan, representing 3.07% of total R&D investment[83] - The company completed process validation for Succinate Metoprolol API and obtained an "Acceptance Notice" on March 29, 2024[82] - The company achieved self-production of 1-Benzyl-3-piperidinol, a key material for Benidipine Hydrochloride, reducing production costs[83] - The company completed small-scale production and the first pilot production of Azulene Sodium Sulfonate, aiming to improve toothpaste quality[83] - The company obtained a "Drug Supplement Approval Notice" for Glipizide Dispersible Tablets on March 29, 2024, enhancing product quality and safety[83] - The company will continue to invest in biopharmaceutical innovation projects in 2024, focusing on the development of new projects based on the recombinant vaccine and new adjuvant technology platforms established by existing R&D projects[158] - The company will optimize the R&D strategy to shorten the development cycle of generic drugs and advance the consistency evaluation of major products[148] - The company will increase R&D and product innovation investment, enrich the product line, and enhance market competitiveness through external cooperation, academic promotion, and brand marketing[165] Business Segments - Pharmaceutical and health products business revenue accounted for 75.85% of total revenue, reaching 1.73 billion RMB, a 15.35% increase year-on-year[26][31] - The company's concrete business revenue increased by 3.76% to 348.59 million RMB[31] - Revenue from the elderly care and medical business grew by 8.25% to 130.12 million RMB[31] - North and Northeast China regions contributed 57.83% of total revenue, reaching 1.32 billion RMB, a 15.74% increase year-on-year[31] - Sales revenue from the western region increased by 3.12% to 250,799,136.79 yuan, accounting for 11.02% of total revenue[44] - Distribution sales increased by 15.35% to 1,726,774,797.92 yuan, accounting for 75.85% of total revenue[44] - Direct sales decreased by 2.38% to 549,828,547.83 yuan, accounting for 24.15% of total revenue[44] - The company's elderly care business has established a comprehensive ecosystem integrating medical, rehabilitation, nursing, and entertainment services[104] - The company's Taizhong Hospital upgraded to a second-level medical institution in 2023, enhancing its reputation and strategic layout in the healthcare sector[105] - The company will focus on increasing the occupancy rate of existing beds in the elderly care business and meeting personalized needs to convert bed advantages into scale advantages[151] - The company plans to deepen customer cooperation in the medical device business to establish long-term stable business relationships[143] - The company will continue to promote the market access of "Yuanzhi" and expand terminal and department coverage to build a business scale "moat"[142] - The company will explore new marketing channels and expand product lines in the "Huasu Yuchuang" series of toothpaste and mouthwash products to capture market share[143] - The company will implement refined management in the elderly care business to improve customer satisfaction and single-bed comprehensive income[151] - The company's elderly care medical business will continue to focus on basic elderly care, with a dual focus on medical care and health care, aiming to improve operational quality and profit contribution through refined management, increased occupancy rates, and enhanced integration of medical and elderly care services[159] Operational Costs and Expenses - Biopharmaceutical segment inventory increased by 66.48% due to the normalization of production and sales post-public health events, and preparation for 2024 New Year and Spring Festival demand[35] - Biopharmaceutical segment's operating cost increased by 28.29% to 510,129,283.94 yuan, accounting for 53.26% of total operating costs[37] - Commercial concrete segment's operating cost decreased by 10.68% to 259,488,801.49 yuan, accounting for 27.09% of total operating costs[37] - Elderly healthcare segment's operating cost increased by 21.23% to 147,331,676.80 yuan, accounting for 15.38% of total operating costs[37] - Total operating costs increased by 9.65% to 957,745,566.86 yuan[37] - Sales expenses increased by 12.57% to 805,451,446.92 yuan[52] - Management expenses increased by 4.16% to 218,612,964.67 yuan, while financial expenses decreased by 16.51% to 53,793,675.92 yuan[64] - R&D expenses decreased by 14.85% to 103,497,279.33 yuan[64] - The company plans to optimize production processes, reduce costs, and improve supply flexibility to shorten supply cycles and enhance supply capacity[141] - The company plans to strengthen production planning management, optimize resource allocation, and enhance production process innovation to ensure the advancement of production equipment and processes[160] Cash Flow and Investments - Net cash flow from operating activities increased by 18.81% to 218,298,525.35 yuan[65] - Net cash flow from investing activities decreased by 77.74% to -117,472,501.71 yuan[65] - Net cash flow from financing activities improved by 78.80% to -34,689,453.46 yuan[65] - Cash and cash equivalents increased by 243.81% to 66,136,480.98 yuan[65] - Tax refunds received decreased by 76.54% to 4,699,700 yuan[66] - Cash received from disposal of subsidiaries increased by 100% to 51,100 yuan[66] - Cash paid for acquisition of subsidiaries increased by 1,623.08% to 50,639,400 yuan[66] - The fair value change loss of financial assets was -1,937,596.08 yuan, resulting in a year-end balance of 5,767,409.73 yuan[78] - Restricted assets totaled 589,877,967.47 yuan, including 153,847,144.27 yuan in investment properties and 417,815,883.01 yuan in fixed assets[79] - Total investment amount for the reporting period was RMB 54.32 million, a decrease of 15.76% compared to the previous year's RMB 64.48 million[99] - Acquired Beijing Wodakang Medical Equipment Co., Ltd. for RMB 24.5 million, achieving a 100% ownership stake[99] - Acquired Beijing Purun Defang Technology Development Co., Ltd. for RMB 3.5 million, achieving a 100% ownership stake[99] - Combined investment profit from the acquisitions amounted to RMB 5.44 million[99] - The total initial investment cost for securities is 5,080,900.00, with a period-end book value of 2,760,813.64, reflecting a significant decrease due to a fair value change loss of 1,937,596.08[111] - The company reported no derivative investments during the reporting period[112] - The total raised funds amounted to 71,000, with a net amount of 69,991.17, and all funds were fully utilized by the end of 2023[114] - The company repaid 19,000 to its controlling shareholder, Guomei Holdings, achieving 100% of the committed investment[115] - The investment in the construction of Shandong Huasu's raw material and solid oral preparation production line reached 6,877.65, achieving 100% of the adjusted investment target[116] - The company invested 1,987.04 in the project to expand the indications for Hydrochloride Phencynonate Tablets and Naltrexone Hydrochloride Tablets, achieving 100% of the adjusted investment target[115] - The brand building project for Huasu Pharmaceutical received an investment of 6,697.3, achieving 100% of the adjusted investment target[116] - The company supplemented its working capital with 4,958.11, achieving 100% of the adjusted investment target[116] - The acquisition of minority equity in Duoduo Pharmaceutical amounted to 12,870.18, achieving 100% of the adjusted investment target[116] - The total investment in committed projects reached 69,991.17, with a total realized benefit of 9,989.71[116] - The drug metabolism platform project has been fully completed with a total investment of 21.01 million yuan, achieving 100% of the planned amount. The project has accumulated a loss of 27.93 million yuan as of 2023[118] - The drug metabolism platform project generated revenue of 2.49 million yuan in 2023, with a loss of 6.02 million yuan for the year[118] - The total investment in the drug metabolism platform project exceeded the planned amount by 13.94 million yuan, primarily due to interest from raised funds[118] - The naltrexone hydrochloride tablet project for alcohol dependence adaptation has exceeded its annual budget by 133.69%, with a total investment of 21.13 million yuan as of 2023[120] - The Shandong Huasu raw material and solid oral preparation production line project achieved a net profit of 105.91 million yuan in 2023, exceeding the expected annual profit of 36.06 million yuan[120] - The Shandong Huasu project has accumulated revenue of 1.84 billion yuan and a net profit of 384.77 million yuan since its inception[120] - The Huasu Pharmaceutical brand building project was completed with a total investment of 66.97 million yuan, and the remaining 9.77 million yuan was used to permanently supplement working capital[120] - All raised funds have been fully utilized as of December 31, 2023, with no remaining unused funds[125] Subsidiaries and Acquisitions - The company completed the acquisition of 100% equity in Beijing Zhongshi Tongda Commercial Concrete Transportation Co., Ltd. and Beijing Wodakang Medical Devices Co., Ltd., making them wholly-owned subsidiaries[37] - The company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has a two-year working capital loan balance of 97 million yuan, secured by land and property in Beijing with a net book value of 49.65 million yuan[90] - Beijing Huasu Pharmaceutical Co., Ltd. has a three-year sale-leaseback business balance of 21.53 million yuan, secured by production equipment with a net book value of 22.5 million yuan[91] - The company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. Cangzhou Branch, has a three-year working capital loan balance of 57.5 million yuan, secured by buildings and industrial land with a net book value of 136.77 million yuan[94] - The company's subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has a one-year working capital loan balance of 48 million yuan, secured by property with a net book value of 63.84 million yuan[94] - Shandong Huasu Pharmaceutical Co., Ltd. has a one-year working capital loan balance of 20 million yuan, secured by property with a net book value of 21.25 million yuan[95] - Shandong Huasu Pharmaceutical Co., Ltd. has a one-year working capital loan balance of 80 million yuan, secured by property with a net book value of 73.28 million yuan[95] - The company's subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has a one-year maximum credit amount contract with a balance of 25 million yuan, secured by patents with a net book value of 85,475.31 yuan[96] - The company's subsidiary, Duoduo Pharmaceutical Co., Ltd., has a one-year working capital loan balance of 45 million yuan, secured by property with a net book value of 57.78 million yuan[97] - The company's property "Haocheng Building" 203 is under court seizure due to litigation, with a net book value of 1.24 million yuan[97] - Beijing Zhongguancun Youth Technology Venture Capital Co., Ltd. reported a net loss of RMB -262,802.58 with total assets of RMB 76,005,444.92[129] - Beijing Zhongshi Concrete Co., Ltd. achieved a net profit of RMB 30,717,659.60 with total assets of RMB 695,135,978.68[129] - Beijing Zhongke Taihe Property Service Co., Ltd. recorded a net profit of RMB 1,329,855.03 with total assets of RMB 21,016,902.66[129] - Beijing Zhongguancun Ke Mao Electronics City Co., Ltd. reported a net loss of RMB -315,516.77 with total assets of RMB 26,077,826.56[129] - Beijing Meilun Real Estate Development Co., Ltd. reported a net loss of RMB -840.00 with total assets of RMB 55,673,746.70[131] - Shandong Zhongguancun Medical Technology Development Co., Ltd. achieved a net profit of RMB 1,734,545.30 with total assets of RMB 302,564,730.72[131] - Chongqing Haide Industrial Co., Ltd. reported a net loss of RMB -3,413,928.68 with total assets of RMB 192,172,912.47[131] - Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd. achieved a net profit of RMB 168,328,953.10 with total assets of RMB 3,049,851,009.04[131] - Shanghai Sitong International Technology Mall Property Co., Ltd. reported a net loss of RMB -254,015.62 with total assets of RMB 70,426,929.05[131] - Beijing Huasu Health Technology Co., Ltd. reported a net loss of RMB -16,619,553.99 with total assets of RMB 33,383,587.26[131] Corporate Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and managers, with the "Compensation and Benefits Management System" and "Performance Evaluation Management System" approved by the Compensation and Evaluation Committee, the fifth board of directors, and the 2012 annual shareholders' meeting[191] - The company maintains independence in business, personnel, assets, organization, and finance, with a complete business system and independent operation capabilities[182][183] - The company's board of directors has four specialized committees: Strategy, Audit, Nomination, and Compensation and Evaluation, which operate effectively and provide important support for decision-making[179] - The company respects the legitimate rights and interests of other stakeholders and encourages employees to communicate directly with

董事会战略委员会工作细则 北京中关村科技发展（控股）股份有限公司 董事会战略委员会工作细则 第一章 总 则 第一条 为适应北京中关村科技发展（控股）股份有限公司（以下简称：公司）战 略发展需要，增强公司发展规划决策的科学性，提高重大投资决策的有效性，完善公司 治理，实现可持续发展，根据《中华人民共和国公司法》《上市公司治理准则》《北京 中关村科技发展（控股）股份有限公司章程》（以下简称：《公司章程》）及其他有关 规定，制定本工作细则。 第二条 战略委员会是董事会下设的专门工作机构，主要负责研究公司长期发展战 略，并对重大投资、资本运作决策进行研究并提出建议。向董事会报告，对董事会负责。 第二章 人员组成 第三条 战略委员会成员由 3 至 5 名董事组成，其中应至少包括 1 名独立董事。 第四条 战略委员会委员由董事长、1/2 以上独立董事或者全体董事的 1/3 提名， 董事会选举产生。 第五条 战略委员会设主任委员 1 名，负责主持工作。主任委员在委员内选举，并 报董事会批准产生。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。期间 如有委员不再担任公司董事职务，自动失去委员资格，并由委 ...

北京中关村科技发展(控股)股份有限公司 内部控制审计报告 内部控制审计报告 中兴财光华审专字(2024)第213151号 北京中关村科技发展(控股)股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了北京中关村科技发展(控股)股份有限公司(以下简称"中关村") 2023年12月 31日的财务报告内部控制的有效性。 中兴财光华审专字(2024)第 213151 号 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效 性是中关村董事会的责任。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.mof.gov.cn） 二、注册会计师的责任 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于 情况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降 低,根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为,中关村于2023年12月31日按 ...

董事会议事规则 北京中关村科技发展（控股）股份有限公司 董事会议事规则 第一章 总 则 第一条 为明确北京中关村科技发展（控股）股份有限公司（以下简称：公司、本 公司）董事会的职责权限，规范公司董事会的议事方式和决策程序，促使公司董事和董 事会有效地履行其职责，提高公司董事会规范运作和科学决策水平，根据《中华人民共 和国公司法》（以下简称：《公司法》）《中华人民共和国证券法》《深圳证券交易所 股票上市规则》等法律、行政法规、规范性文件以及《北京中关村科技发展（控股）股 份有限公司章程》（以下简称：《公司章程》）的规定，制定本规则。 第二条 公司董事会及其成员除遵守《公司法》、其他法律、法规和《公司章程》 外，亦应遵守本规则的规定。 第三条 在本规则中，董事会指公司董事会；董事指公司所有董事。 第四条 在公司存续期间，均应设置董事会，对股东大会负责。 第二章 董事会的组成及职权 第五条 董事会由九名董事组成，其中独立董事占董事会成员的 1/3 以上。董事会 设董事长一名，副董事长一名。 董事会成员中可以有公司职工代表。董事会中的职工代表由公司职工通过职工代表 大会民主选举产生后，直接进入董事会。 第六条 董事由 ...

关于修订《公司章程》及部分治理制度的公告 共 20 页 证券代码：000931 证券简称：中关村 公告编号：2024-034 北京中关村科技发展（控股）股份有限公司 关于修订《公司章程》及部分治理制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2024 年 4 月 17 日召开了第八届董事会第六次会议，审议并通过了《关于修订<公司章程> 的议案》及《关于修订部分公司治理制度的议案》；于 2024 年 4 月 17 日召开了 第八届监事会第六次会议，审议并通过了《关于修订<监事会议事规则>的议案》。 现将具体情况公告如下： 一、《公司章程》修订情况 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程 指引》《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法 规、规范性文件的相关规定，结合公司实际情况，提议对《公司章程》部分条款 进行修订。 | 序 | 号 | 修订前条款 | 修订后条款 ...